Article Text

Download PDFPDF

British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults
  1. Jonathon Snook1,
  2. Neeraj Bhala2,
  3. Ian L P Beales3,
  4. David Cannings1,
  5. Chris Kightley4,
  6. Robert PH Logan5,
  7. D Mark Pritchard6,
  8. Reena Sidhu7,
  9. Sue Surgenor1,
  10. Wayne Thomas8,
  11. Ajay M Verma4,
  12. Andrew F Goddard9
  1. 1 Gastroenterology, University Hospitals Dorset NHS Foundation Trust, Poole, UK
  2. 2 Gastroenterology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust and Institute of Applied Health Research, University of Birmingham, Birmingham, UK
  3. 3 Gastroenterology, University of East Anglia, Norwich, UK
  4. 4 Digestive Diseases, Kettering General Hospital NHS Foundation Trust, Kettering, UK
  5. 5 Gastroenterology, Kings College Hospital, London, UK
  6. 6 Institute of Systems, Molecular and Integrative Biology, University of Liverpool and Department of Gastroenterology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
  7. 7 Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK
  8. 8 Haematology, Plymouth Hospitals NHS Foundation Trust, Plymouth, Plymouth, UK
  9. 9 Gastroenterology, Royal Derby Hospital, Derby, UK
  1. Correspondence to Dr Jonathon Snook, Gastroenterology, University Hospitals Dorset NHS Foundation Trust, Poole, Dorset, UK; jonathon.snook{at}gmail.com

Abstract

Iron deficiency anaemia (IDA) is a major cause of morbidity and burden of disease worldwide. It can generally be diagnosed by blood testing and remedied by iron replacement therapy (IRT) using the oral or intravenous route. The many causes of iron deficiency include poor dietary intake and malabsorption of dietary iron, as well as a number of significant gastrointestinal (GI) pathologies. Because blood is iron-rich it can result from chronic blood loss, and this is a common mechanism underlying the development of IDA—for example, as a consequence of menstrual or GI blood loss.

Approximately a third of men and postmenopausal women presenting with IDA have an underlying pathological abnormality, most commonly in the GI tract. Therefore optimal management of IDA requires IRT in combination with appropriate investigation to establish the underlying cause. Unexplained IDA in all at-risk individuals is an accepted indication for fast-track secondary care referral in the UK because GI malignancies can present in this way, often in the absence of specific symptoms. Bidirectional GI endoscopy is the standard diagnostic approach to examination of the upper and lower GI tract, though radiological scanning is an alternative in some situations for assessing the large bowel. In recurrent or refractory IDA, wireless capsule endoscopy plays an important role in assessment of the small bowel.

IDA may present in primary care or across a range of specialties in secondary care, and because of this and the insidious nature of the condition it has not always been optimally managed despite the considerable burden of disease— with investigation sometimes being inappropriate, incorrectly timed or incomplete, and the role of IRT for symptom relief neglected. It is therefore important that contemporary guidelines for the management of IDA are available to all clinicians. This document is a revision of previous British Society of Gastroenterology guidelines, updated in the light of subsequent evidence and developments.

  • iron deficiency
  • anaemia
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • JS and NB are joint first authors.

  • Twitter @nijbhala, @gastrolivuni, @drreenasidhu1, @UKGastroDr, @bodgoddard

  • Correction notice This article has been corrected since it published Online First. Affiliation number 6 and table 4 have been updated.

  • Contributors All coauthors contributed material for and amendments to the original draft, and approved the final version for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ILPB: Vifor advisory board, Pharmcosmos advisory board; PI for Feraccru studies. RL: Vifor Advisory Board, NHS England advisor. MP: Trio Medicines (research funding); IPSEN, Advanced Accelerator Applications, Mayoly Spindler laboratories (consultancies). AMV, WT, RS, CK, DC, NB, SS, AFG, JS: none declared.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Provenance and peer review Not commissioned; externally peer reviewed.